to-BBB and GSK to collaborate on brain delivery of a biologic product
to-BBB announced that it has entered into a research collaboration with GlaxoSmithKline (GSK) involving to-BBB’s proprietary G-Technology® in delivering a biological compound to the brain.
Under the terms of the collaboration, to-BBB will work with scientists at the GSK R&D centre in Shanghai, China to further evaluate the brain delivery of treatments enhanced with to-BBB’s G-Technology.
G-Technology is designed to enhance transport of medicines across the blood-brain barrier by encapsulating these compounds into proprietary glutathione coated liposomes. The company has shown proof of concept in different disease models and GSK will now assess the technology with GSK nominated compounds.
“We look forward to working with the scientists at GSK R&D China.” says Pieter Gaillard, CSO of to-BBB. “Combining the expertise of GSK in the area of neurobiology with to-BBB’s brain targeting knowledge, we hope will lead to advances in the treatment of diseases that affect the brain.”
Other news from the department business & finance
